Vedaprofen is a chiral nonsteroidal anti-inflammatory drug that has been developed as a gel formulation for oral administration to dogs and horses. The pharmacokinetics of vedaprofen and its enantiomers were studied in beagle dogs after single (intravenous solution and oral gel) and multiple (oral gel) dosing at a dosage of 0.5 mg/kg body weight. Plasma concentrations of vedaprofen and its enantiomers were analysed by HPLC. The plasma protein binding of vedaprofen was studied by ultrafiltration. The absorption of vedaprofen was rapid (tmax 0.63 ± 0.14 h) and almost complete after oral administration (bioavailability 86 ± 7%). The terminal half-lives after intravenous and oral administration, 16.8 ± 2.2 and 12.7 ± 1.7 h respectively, were of the same order of magnitude. Enantioselective analysis showed that the R(−) enantiomer predominated in plasma. The change in the plasma time course of the plasma R(−)/S(+) enantiomer concentration ratio over time was similar after single intravenous and oral dosing, with R(−)/S(+) ratios in the AUC of 1.7 ± 0.5 and 1.9 ± 0.2 respectively. Plasma protein binding of vedaprofen and its enantiomers was high (>99.5%). Vedaprofen is absorbed rapidly from the gastrointestinal tract, has a high bioavailability and does not accumulate in plasma in dogs following repeated oral administration.